Filing Details

Accession Number:
0000905148-25-002298
Form Type:
13D Filing
Publication Date:
2025-06-30 20:00:00
Filed By:
Viking Global
Company:
Bridgebio Pharma Inc. (NASDAQ:BBIO)
Filing Date:
2025-07-01
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
VIKING GLOBAL INVESTORS LP 0 18,602,920 0 18,602,920 18,602,920 9.8%
VIKING GLOBAL PERFORMANCE LLC 0 339,695 0 339,695 339,695 0.2%
Viking Global Equities II LP 0 6,794 0 6,794 6,794 0%
Viking Global Equities Master Ltd. 0 332,901 0 332,901 332,901 0.2%
Viking Long Fund GP LLC 0 118,214 0 118,214 118,214 0.1%
Viking Long Fund Master Ltd. 0 118,214 0 118,214 118,214 0.1%
Viking Global Opportunities Parent GP LLC 0 18,145,011 0 18,145,011 18,145,011 9.6%
Viking Global Opportunities GP LLC 0 18,145,011 0 18,145,011 18,145,011 9.6%
Viking Global Opportunities Portfolio GP LLC 0 18,145,011 0 18,145,011 18,145,011 9.6%
Viking Global Opportunities Illiquid Investments Sub-Master LP 0 18,089,980 0 18,089,980 18,089,980 9.5%
Viking Global Opportunities Liquid Portfolio Sub-Master LP 0 55,031 0 55,031 55,031 0.03%
HALVORSEN OLE ANDREAS 0 18,602,920 0 18,602,920 18,602,920 9.8%
Ott David C. 0 18,602,920 0 18,602,920 18,602,920 9.8%
Shabet Rose Sharon 0 18,602,920 0 18,602,920 18,602,920 9.8%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
All share percentage calculations in this Amendment No. 7 to the Schedule 13D are based on 189,880,720 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025.


SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D

 
VIKING GLOBAL INVESTORS LP
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:07/01/2025
 
VIKING GLOBAL PERFORMANCE LLC
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3)
Date:07/01/2025
 
Viking Global Equities II LP
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
Date:07/01/2025
 
Viking Global Equities Master Ltd.
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
Date:07/01/2025
 
Viking Long Fund GP LLC
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
Date:07/01/2025
 
Viking Long Fund Master Ltd.
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
Date:07/01/2025
 
Viking Global Opportunities Parent GP LLC
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:07/01/2025
 
Viking Global Opportunities GP LLC
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:07/01/2025
 
Viking Global Opportunities Portfolio GP LLC
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:07/01/2025
 
Viking Global Opportunities Illiquid Investments Sub-Master LP
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:07/01/2025
 
Viking Global Opportunities Liquid Portfolio Sub-Master LP
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Liquid Portfolio Sub-Master LP (1)(2)(3)
Date:07/01/2025
 
HALVORSEN OLE ANDREAS
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:07/01/2025
 
Ott David C.
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Ott David C. (2)
Date:07/01/2025
 
Shabet Rose Sharon
 
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Shabet Rose Sharon (3)
Date:07/01/2025
Comments accompanying signature:
(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).